120 related articles for article (PubMed ID: 35729543)
1. The effect of COVID-19 on prostate cancer testing in Australia.
Jain A; Macneil J; Kim L; Patel MI
BMC Urol; 2022 Jun; 22(1):88. PubMed ID: 35729543
[TBL] [Abstract][Full Text] [Related]
2. Spatial patterns of prostate-specific antigen testing in asymptomatic men across Australia: a population-based cohort study, 2017-2018.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Public Health; 2023 Apr; 217():173-180. PubMed ID: 36898290
[TBL] [Abstract][Full Text] [Related]
3. Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
Ng Hung Shin B; Tan S; Rhee H; Chung E
Int J Cancer; 2024 Mar; 154(6):1003-1010. PubMed ID: 37921494
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic.
Kaufman HW; Chen Z; Niles JK; Radcliff J; Fesko Y
JCO Clin Cancer Inform; 2021 Sep; 5():1028-1033. PubMed ID: 34648367
[TBL] [Abstract][Full Text] [Related]
5. Changes in prostate specific antigen (PSA) "screening" patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Cancer Epidemiol; 2023 Apr; 83():102338. PubMed ID: 36841020
[TBL] [Abstract][Full Text] [Related]
6. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
7. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
[TBL] [Abstract][Full Text] [Related]
8. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts.
Epstein MM; Sundaresan D; Fair M; Fouayzi H; Warner ET; Garber LD; Gurwitz JH; Field TS
Cancer Causes Control; 2022 Oct; 33(10):1313-1323. PubMed ID: 35933572
[TBL] [Abstract][Full Text] [Related]
9. Patterns of prostate-specific antigen testing by remoteness of residence and socio-economic status: An Australian population-based study.
Calopedos RJS; Bang A; Baade P; Yu XQ; Ruthven S; Patel MI; Smith DP
Aust J Rural Health; 2019 Jun; 27(3):216-223. PubMed ID: 31070837
[TBL] [Abstract][Full Text] [Related]
10. Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.
Luo Q; Yu XQ; Kahn C; Egger S; Patel MI; Grogan PB; Caruana M; Canfell K; Smith DP; O'Connell DL
Cancer Epidemiol; 2022 Jun; 78():102159. PubMed ID: 35447540
[TBL] [Abstract][Full Text] [Related]
11. Better Access: substantial shift to telehealth for allied mental health services during COVID-19 in Australia.
Reay R; Kisely SR; Looi JCL
Aust Health Rev; 2021 Dec; 45(6):675-682. PubMed ID: 34743787
[TBL] [Abstract][Full Text] [Related]
12. Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.
Dantanarayana ND; Hossack T; Cozzi P; Brooks A; Lau H; Delprado W; Patel MI
BMC Urol; 2015 Dec; 15():124. PubMed ID: 26715039
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
Bunting PS; Chong N; Holowaty EJ; Goel V
Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
[TBL] [Abstract][Full Text] [Related]
14. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
15. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales.
Smith DP; Armstrong BK
Med J Aust; 1998 Jul; 169(1):17-20. PubMed ID: 9695696
[TBL] [Abstract][Full Text] [Related]
17. PSA testing for men at average risk of prostate cancer.
Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
[TBL] [Abstract][Full Text] [Related]
18. Geospatial and temporal variation of prostate cancer incidence.
Wah W; Ahern S; Evans S; Millar J; Evans M; Earnest A
Public Health; 2021 Jan; 190():7-15. PubMed ID: 33321358
[TBL] [Abstract][Full Text] [Related]
19. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
20. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
